Oncology Other Current Liab from 2010 to 2024

TOIIW Stock  USD 0.02  0  26.85%   
Oncology Institute Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities will likely drop to about 11.2 M in 2024. During the period from 2010 to 2024, Oncology Institute Other Current Liabilities regression line of quarterly data had mean square error of 6 T and geometric mean of  6,243,727. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
13.5 M
Current Value
11.2 M
Quarterly Volatility
3.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 7.1 M or Selling General Administrative of 67.6 M, as well as many indicators such as Price To Sales Ratio of 0.44, Dividend Yield of 0.0235 or PTB Ratio of 2.51. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
Check out the analysis of Oncology Institute Correlation against competitors.
For more information on how to buy Oncology Stock please use our How to Invest in Oncology Institute guide.

Latest Oncology Institute's Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of The Oncology Institute over the last few years. It is Oncology Institute's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Oncology Other Current Liab Regression Statistics

Arithmetic Mean6,958,257
Geometric Mean6,243,727
Coefficient Of Variation53.36
Mean Deviation3,129,011
Median4,700,020
Standard Deviation3,713,116
Sample Variance13.8T
Range8.8M
R-Value0.77
Mean Square Error6T
R-Squared0.60
Significance0.0007
Slope641,885
Total Sum of Squares193T

Oncology Other Current Liab History

202411.2 M
202313.5 M
202213.3 M
202113.3 M
20206.1 M

About Oncology Institute Financial Statements

Oncology Institute investors use historical fundamental indicators, such as Oncology Institute's Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncology Institute. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities13.5 M11.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncology Stock Analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.